[go: up one dir, main page]

CA2692576A1 - Procede pour determiner l'activite du facteur von willebrand en l'absence de ristocetine et celle de la protease adamts-13 - Google Patents

Procede pour determiner l'activite du facteur von willebrand en l'absence de ristocetine et celle de la protease adamts-13 Download PDF

Info

Publication number
CA2692576A1
CA2692576A1 CA 2692576 CA2692576A CA2692576A1 CA 2692576 A1 CA2692576 A1 CA 2692576A1 CA 2692576 CA2692576 CA 2692576 CA 2692576 A CA2692576 A CA 2692576A CA 2692576 A1 CA2692576 A1 CA 2692576A1
Authority
CA
Canada
Prior art keywords
vwf
alpha
gpib
protein
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2692576
Other languages
English (en)
Other versions
CA2692576C (fr
Inventor
Harald Althaus
Tobias Obser
Juergen Patzke
Reinhard Schneppenheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics Products GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2938781A priority Critical patent/CA2938781C/fr
Publication of CA2692576A1 publication Critical patent/CA2692576A1/fr
Application granted granted Critical
Publication of CA2692576C publication Critical patent/CA2692576C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553—Metal or metal coated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2692576A 2007-07-06 2008-07-03 Procede pour determiner l'activite du facteur von willebrand en l'absence de ristocetine et celle de la protease adamts-13 Active CA2692576C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2938781A CA2938781C (fr) 2007-07-06 2008-07-03 Procede pour determiner l'activite du facteur von willebrand en l'absence de ristocetine et celle de la protease adamts-13

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007031708A DE102007031708A1 (de) 2007-07-06 2007-07-06 Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
DE102007031708.7 2007-07-06
PCT/EP2008/005416 WO2009007051A2 (fr) 2007-07-06 2008-07-03 Procédé pour déterminer l'activité du facteur von willebrand en l'absence de ristocétine et celle de la protéase adamts-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2938781A Division CA2938781C (fr) 2007-07-06 2008-07-03 Procede pour determiner l'activite du facteur von willebrand en l'absence de ristocetine et celle de la protease adamts-13

Publications (2)

Publication Number Publication Date
CA2692576A1 true CA2692576A1 (fr) 2009-01-15
CA2692576C CA2692576C (fr) 2016-11-01

Family

ID=40092552

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2938781A Active CA2938781C (fr) 2007-07-06 2008-07-03 Procede pour determiner l'activite du facteur von willebrand en l'absence de ristocetine et celle de la protease adamts-13
CA2692576A Active CA2692576C (fr) 2007-07-06 2008-07-03 Procede pour determiner l'activite du facteur von willebrand en l'absence de ristocetine et celle de la protease adamts-13

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2938781A Active CA2938781C (fr) 2007-07-06 2008-07-03 Procede pour determiner l'activite du facteur von willebrand en l'absence de ristocetine et celle de la protease adamts-13

Country Status (9)

Country Link
US (4) US9222942B2 (fr)
EP (2) EP2388596B1 (fr)
JP (2) JP5745270B2 (fr)
CN (3) CN104897910B (fr)
BR (1) BRPI0814056A2 (fr)
CA (2) CA2938781C (fr)
DE (1) DE102007031708A1 (fr)
ES (2) ES2425797T3 (fr)
WO (1) WO2009007051A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007031708A1 (de) 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
EP2193373A4 (fr) * 2007-08-23 2010-07-28 Bloodct Of Wisconsin Inc Procédés et kits pour mesurer le facteur von willebrand
CA2757585C (fr) * 2010-11-17 2022-07-19 Puget Sound Blood Center Clivage ameliore du facteur de von willebrand par adamts13
CN102279273A (zh) * 2011-07-19 2011-12-14 苏州大学 一种血管性血友病因子瑞斯托霉素辅因子酶联免疫试剂盒
EP2634577A1 (fr) 2012-02-29 2013-09-04 Siemens Healthcare Diagnostics Products GmbH Procédé de détection d'interférences dans des tests de diagnostic in vitro
EP2637024A1 (fr) * 2012-03-05 2013-09-11 Siemens Healthcare Diagnostics Products GmbH Procédé de criblage destiné à la recherche d'échantillons ayant une défaillance de fonctionnalité de l'interaction du facteur GPIb de Willbrand
EP2708892B1 (fr) 2012-09-18 2015-04-15 Siemens Healthcare Diagnostics Products GmbH Méthode pour la détermination d'analytes associés aux thrombocytes
EP2829878A1 (fr) 2013-07-23 2015-01-28 Siemens Healthcare Diagnostics Products GmbH Procédé de détermination de la fonction plaquettaire en fonction du récepteur GPIb
EP2919013B1 (fr) * 2014-03-11 2016-11-02 Siemens Healthcare Diagnostics Products GmbH Procédé de détection de modulateurs de l'interaction GPIb-Thrombine
WO2018071502A1 (fr) 2016-10-11 2018-04-19 Laboratory Corporation Of America Holdings Méthodes et systèmes pour déterminer une activité enzymatique adamts13
UY38092A (es) * 2018-02-20 2019-05-31 Solicitante Grifols Diagnostic Solutions Inc COMPOSICIÓN QUE COMPRENDE UNA PROTEÍNA RECOMBINANTE RECEPTORA GPIba
CN110785499B (zh) 2018-05-25 2024-12-03 伊鲁米那股份有限公司 对先兆子痫具有特异性的循环rna标识
JP2023501760A (ja) 2019-11-22 2023-01-19 イルミナ インコーポレイテッド 子癇前症に特異的な循環ｒｎａシグネチャー
EP4585926A1 (fr) 2024-01-09 2025-07-16 Siemens Healthcare Diagnostics Products GmbH Procédé et kit pour réduire les interférences dans des dosages immunologiques

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
IL88308A0 (en) 1987-11-17 1989-06-30 Scripps Clinic Res Peptides that block the binding of von willebrand factor
NZ237244A (en) 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
US5317097A (en) 1991-10-07 1994-05-31 The Research Foundation Of State University Of New York Mutations in the gene encoding the α chain on platelet glycoprotein IB
AU3734793A (en) 1992-02-26 1993-09-13 Scripps Research Institute, The Mutant gpibalpha fragments and recombinant expression thereof
AU756563B2 (en) 1999-02-25 2003-01-16 Baxter Aktiengesellschaft Test kit for analysing factor VIII-splitting protease
ES2358576T3 (es) * 1999-07-05 2011-05-11 K.U. LEUVEN RESEARCH & DEVELOPMENT Detección de la actividad del factor de von-willebrand (vwf).
AR035779A1 (es) * 2001-02-06 2004-07-14 Genetics Inst Llc Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos
CN1211400C (zh) 2001-09-18 2005-07-20 中国人民解放军军事医学科学院野战输血研究所 人血小板糖蛋白GPIbα的制备方法及其专用引物
DE20213920U1 (de) * 2002-07-03 2003-01-16 Böhm, Martina, 60439 Frankfurt Diagnostikum zum Nachweis der den von Willebrand-Faktorspaltenden Aktivität von ADAMTS13
JP3944586B2 (ja) 2002-10-18 2007-07-11 国立循環器病センター総長 フォンビルブランド因子切断酵素の特異的基質および活性測定法
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
MXPA05013509A (es) * 2003-06-11 2006-04-05 Wyeth Corp Polipeptidos de fusion de variante ib alfa de glucoproteina de plaquetas y metodos y uso de los mismos.
JP5112692B2 (ja) * 2003-07-07 2013-01-09 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル フォンビルブランド因子（ｖｗｆ）マルチマーを検出する方法およびシステム
US20050186646A1 (en) * 2004-01-26 2005-08-25 Cruz Miguel A. Rapid assay to detect ADAMTS-13 activity
AU2005258000B2 (en) * 2004-06-21 2011-02-03 Progenra Inc. Diagnostic and screening methods and kits associated with proteolytic activity
TWI367260B (en) * 2005-03-18 2012-07-01 Univ Hong Kong Chinese Method for detecting the presence of a fetus with trisomy 21 in a pregnant woman and kit thereof
EP1736481A1 (fr) * 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Variants d'érythropoietine
DE102007031708A1 (de) 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
EP2193373A4 (fr) * 2007-08-23 2010-07-28 Bloodct Of Wisconsin Inc Procédés et kits pour mesurer le facteur von willebrand
EP2637024A1 (fr) * 2012-03-05 2013-09-11 Siemens Healthcare Diagnostics Products GmbH Procédé de criblage destiné à la recherche d'échantillons ayant une défaillance de fonctionnalité de l'interaction du facteur GPIb de Willbrand

Also Published As

Publication number Publication date
US20130078652A1 (en) 2013-03-28
US20160231331A1 (en) 2016-08-11
US9869683B2 (en) 2018-01-16
CN103076459B (zh) 2015-04-29
US8932820B2 (en) 2015-01-13
US9222942B2 (en) 2015-12-29
CA2938781C (fr) 2018-04-24
US10591490B2 (en) 2020-03-17
JP2014036663A (ja) 2014-02-27
BRPI0814056A2 (pt) 2015-01-06
EP2388596B1 (fr) 2013-05-22
US20100136589A1 (en) 2010-06-03
ES2554162T3 (es) 2015-12-16
CN103076459A (zh) 2013-05-01
JP5745270B2 (ja) 2015-07-08
EP2167978B1 (fr) 2015-10-28
WO2009007051A2 (fr) 2009-01-15
CA2938781A1 (fr) 2009-01-15
CA2692576C (fr) 2016-11-01
JP2010532467A (ja) 2010-10-07
DE102007031708A1 (de) 2009-01-08
CN104897910B (zh) 2017-09-29
WO2009007051A3 (fr) 2009-05-28
CN101755211A (zh) 2010-06-23
JP5802968B2 (ja) 2015-11-04
EP2388596A1 (fr) 2011-11-23
EP2167978A2 (fr) 2010-03-31
US20180088133A1 (en) 2018-03-29
ES2425797T3 (es) 2013-10-17
CN104897910A (zh) 2015-09-09

Similar Documents

Publication Publication Date Title
CA2692576C (fr) Procede pour determiner l'activite du facteur von willebrand en l'absence de ristocetine et celle de la protease adamts-13
Levy et al. ADAMTS13 turns 3
Yeh et al. Disulfide bond reduction of von Willebrand factor by ADAMTS‐13
Harris et al. Von Willebrand factor and disease: a review for laboratory professionals
KR20110104940A (ko) 폰빌레브란트 인자의 ａｄａｍｔｓ１３－매개 생체내 절단을 측정하는 방법 및 그의 사용
Ahamed et al. In vitro and in vivo evidence that thrombospondin-1 (TSP-1) contributes to stirring-and shear-dependent activation of platelet-derived TGF-β1
AU2011218228A1 (en) Compositions and methods for the detection of antibodies to native human leukocyte antigen
US9766234B2 (en) Screening process for finding samples having a functionality disorder of the GPIb-von willebrand factor interaction
US11067572B2 (en) Methods and assays for factor VIII activity
Sabino et al. Development of a collagen-binding activity assay as a screening test for type II von Willebrand disease in dogs
AU2006205700A1 (en) Forms of factor XIIa
US20190227084A1 (en) Assay kit and method for detecting modulators of gpib-thrombin interaction
Joubert Characterisation of the fibrinolytic system and the von Willebrand Factor-ADAMTS13 axis in the Chacma baboon
Laugen et al. Hereditary dysfibrinogenemia characterized by slow fibrinopeptide release and competitive inhibition of thrombin
AIHARA et al. Factor XIII is not involved in human platelet-collagen interaction
Grillberger Functional characterization of affinity purified anti-ADAMTS13 IgG autoantibodies from patients with acquired thrombotic thrombocytopenic purpura and a healthy donor pool
WO2017219078A1 (fr) Régulation allostérique de l'activité hémostatique
Hulstein Active Von Willebrand Factor, thrombocytopenia and thrombosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130507